Literature DB >> 16969836

Myeloid dendritic cells in inclusion-body myositis and polymyositis.

Steven A Greenberg1, Geraldine S Pinkus, Anthony A Amato, Jack L Pinkus.   

Abstract

Dendritic cells (DCs), immune system cells central to the development of immunity, have not previously been reported in muscle in inclusion-body myositis (IBM). We performed immunohistochemical studies on muscle biopsy specimens from 50 patients using monoclonal antibodies that distinguish two classes of DCs, myeloid DC and plasmacytoid DC. In 17 of 20 IBM and 9 of 10 polymyositis (PM) specimens, myeloid DCs were present in substantial numbers, frequently surrounded and sometimes invading otherwise intact myofibers, and were part of dense collections of cells that included T cells. Dermatomyositis muscle had more plasmacytoid DCs than myeloid DCs, whereas IBM and PM had greater numbers of myeloid DCs. The stellate morphology of myeloid DCs in dense collections of cells that included T cells suggests local intramuscular antigen presentation in IBM and PM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16969836     DOI: 10.1002/mus.20649

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  31 in total

1.  Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.

Authors:  Sheela Shrestha; Barry Wershil; John F Sarwark; Timothy B Niewold; Teresa Philipp; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2010-09

2.  Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.

Authors:  Ronan J Walsh; Sek Won Kong; Yihong Yao; Bahija Jallal; Peter A Kiener; Jack L Pinkus; Alan H Beggs; Anthony A Amato; Steven A Greenberg
Journal:  Arthritis Rheum       Date:  2007-11

Review 3.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

4.  Distinct inflammatory properties of late-activated macrophages in inflammatory myopathies.

Authors:  K M Rostasy; J Schmidt; E Bahn; T Pfander; M Piepkorn; E Wilichowski; J Schulz-Schaeffer
Journal:  Acta Myol       Date:  2008-10

5.  The inflammatory milieu in idiopathic inflammatory myositis.

Authors:  Ann M Reed; Floranne Ernste
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 6.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 7.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 8.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 9.  A critical role for immature muscle precursors in myositis.

Authors:  Anne Tournadre; Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2013-03-12       Impact factor: 20.543

Review 10.  [Myositides].

Authors:  A Bornemann; S Heitmann; A Lindner
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.